Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.

abstract：OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

journal_title：Journal of medical economics

authors： Copher R,Cerulli A,Watkins A,Laura Monsalvo M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:To compare 1-year costs and benefits of dapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, with those of other treatments for type 2 diabetes (T2D), such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sulfonylureas (SUs), thiazolidinediones (TZDs), and dipeptidyl peptidase-4 ...

journal_title：Journal of medical economics

authors： Chakravarty A,Rastogi M,Dhankhar P,Bell KF

更新日期：2018-05-01 00:00:00

abstract：OBJECTIVE:To estimate the cost-effectiveness of ipilimumab (3 mg/kg) compared with best supportive care (BSC) in pre-treated advanced melanoma patients. METHODS:The analysis was based on a US payer perspective and lifetime time horizon. A three-state Markov model was developed representing clinical outcomes, quality-o...

journal_title：Journal of medical economics

authors： Barzey V,Atkins MB,Garrison LP,Asukai Y,Kotapati S,Penrod JR

更新日期：2013-01-01 00:00:00

abstract：AIMS:Access to Critical Cerebral Emergency Support Services (ACCESS) was developed as a low-cost solution to providing neuro-emergent consultations to rural hospitals in New Mexico that do not offer comprehensive stroke care. ACCESS is a two-way audio-visual program linking remote emergency department physicians and th...

journal_title：Journal of medical economics

authors： Whetten J,van der Goes DN,Tran H,Moffett M,Semper C,Yonas H

更新日期：2018-04-01 00:00:00

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Efficient use of government funding has been increasingly relevant for the success and sustainability of ongoing health-system reform in China; however, as there is no generic substitution policy, patients and basic health-insurance programs pay more for public-preferred brand originators. Such phenomenon is...

journal_title：Journal of medical economics

authors： Sun J,Ren L,Wirtz V

更新日期：2016-09-01 00:00:00

abstract：BACKGROUND:Neuroblastoma (NB) is notorious in childhood cancer because of its high incidence and poor prognosis. The Children's Oncology Group reported that the 3-year OS in the high-risk (HR) group is 50%, and the HR-NB with bone marrow metastasis in our center is 43.1%. Thousands of families in China suffer from the ...

journal_title：Journal of medical economics

authors： Jiang C,Cai S,Duan C,Xu N,Zhou Y,Peng X,Ma X

更新日期：2020-09-01 00:00:00

abstract：OBJECTIVES:To describe the changes in resource utilization in seven European countries (Germany, Greece, Portugal, Romania, Sweden, Spain, and Turkey) and direct costs in four European countries (Germany, Spain, Sweden, and Greece) over the first 12 months of insulin treatment in patients with type 2 diabetes mellitus ...

journal_title：Journal of medical economics

authors： Brismar K,Benroubi M,Nicolay C,Schmitt H,Giaconia J,Reaney M

更新日期：2013-08-01 00:00:00

abstract：AIM:Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk ...

journal_title：Journal of medical economics

authors： Mendoza RL

更新日期：2020-09-01 00:00:00

abstract：OBJECTIVE:The Affordable Care Act (ACA) established the Hospital-Acquired Condition (HAC) Reduction Program. The Centers for Medicare and Medicaid Services (CMS) established a total HAC scoring methodology to rank hospitals based upon their HAC performance. Hospitals that rank in the lowest quartile based on their HAC ...

journal_title：Journal of medical economics

authors： Saitone TL,Sexton RJ,Sexton Ward A

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to describe the economic burden to managed care associated with failure of selective serotonin reuptake inhibitor (SSRI) therapy in terms of direct medical costs. METHODS:A retrospective analysis of the PharMetrics database, a national managed care medical and pharmacy claims ...

journal_title：Journal of medical economics

authors： Balkrishnan R,Joish VN,Yang T,Jayawant SS,Mullins CD

更新日期：2008-01-01 00:00:00

abstract：AIMS:Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The six dimensions have been described separately: (δ1) cost-effectiveness analysis and cost-utility analysis-based pricing; (δ2) willingness-to-pay-based pricing; (δ3) reference-based pricing; (δ4) safety-based pricing; (δ5...

journal_title：Journal of medical economics

authors： Alkhatib NS,McBride A,Slack M,Bhattacharjee S,Erstad B,Ramos K,Abraham I

更新日期：2020-11-01 00:00:00

abstract：OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...

journal_title：Journal of medical economics

authors： Ivanova JI,Kelkar S,King S,Birnbaum HG,Hocker S,Phipps R,Lankow R

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

journal_title：Journal of medical economics

authors： Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

更新日期：2010-01-01 00:00:00

abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...

journal_title：Journal of medical economics

authors： Potter BJ,Ann Thompson C

更新日期：2019-10-01 00:00:00

abstract：BACKGROUND:Alemtuzumab and natalizumab are approved as second-line therapies for relapsing-remitting multiple sclerosis (RRMS) patients in Iran who have shown an inadequate response to other disease-modifying therapy (DMT). In the absence of head-to-head trials, evaluations based on decision analytic modeling may be a ...

journal_title：Journal of medical economics

authors： Taheri S,Sahraian MA,Yousefi N

更新日期：2019-01-01 00:00:00

abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...

journal_title：Journal of medical economics

authors： Rubin RJ,Glaspy JA,Adams JL,Mafilios MS,Wang SM,Viswanathan HN,Kallich JD

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...

journal_title：Journal of medical economics

authors： Johnson BH,Palmer L,Gatwood J,Lenhart G,Kawai K,Acosta CJ

更新日期：2016-10-01 00:00:00

abstract：:Aims: This study aimed to examine the long-term clinical and economic burden of adults with congenital heart disease (ACHD) in Hong Kong. Methods: It retrospectively analyzed 336 consecutive ACHD patients who attended the Adult Congenital Heart Clinic between January 1, 2009 and December 31, 2014. Direct medical costs...

journal_title：Journal of medical economics

authors： Lee VWY,Yan BP,Fong TMC,Fung AKP,Cheng FWT

更新日期：2019-08-01 00:00:00

abstract：OBJECTIVES:To determine the cost effectiveness of sevelamer vs calcium carbonate in patients with chronic kidney disease and not on dialysis (CKD-ND) from the perspective of the National Health Service (NHS) in the UK. METHODS:A Markov decision analytic model was developed to estimate (1) total life years (LYs), quali...

journal_title：Journal of medical economics

authors： Thompson M,Bartko-Winters S,Bernard L,Fenton A,Hutchison C,Di Iorio B

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:Prostate cancer is a leading cause of cancer death in men in the US. Castration-resistant prostate cancer (CRPC) is an advanced form of the disease and has a poor prognosis and limited treatment options. The objective of this study was to identify patients with CRPC from a medical claims database, and determi...

journal_title：Journal of medical economics

authors： Alemayehu B,Buysman E,Parry D,Becker L,Nathan F

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND AND AIMS:Randomized controlled trials have shown that a once-daily prolonged-release (PR) tacrolimus formulation (PR tacrolimus; Advagraf * ), is non-inferior to a twice-daily immediate-release (IR) tacrolimus formulation (IR tacrolimus; Prograf † ) in terms of biopsy-proven acute rejection, graft failure an...

journal_title：Journal of medical economics

authors： Muduma G,Odeyemi I,Pollock RF

更新日期：2014-07-01 00:00:00

abstract：INTRODUCTION:Switching drugs from prescription to non-prescription status (Rx-to-OTC) presents a unique set of challenges and opportunities to policy-makers and the industry in terms of managing health outcomes, pharmaceutical spending, and steering of consumer choices of therapy. Decision-analytic models are used to a...

journal_title：Journal of medical economics

authors： Cohen J,Millier A,Karray S,Toumi M

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes. METHODS:Women receiving first-line chemother...

journal_title：Journal of medical economics

authors： Camacho FT,Wu J,Wei W,Kimmick G,Anderson RT,Balkrishnan R

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients w...

journal_title：Journal of medical economics

authors： Godman B

更新日期：2015-01-01 00:00:00

abstract：:Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. Methods: This retrospective study identified a group of patients with newly-developed mCRPC from 2012 to 2016 to extract information fr...

journal_title：Journal of medical economics

authors： Qian Z,Wang Y,Tang Z,Ren D,Wang Z,Chen W,Li Z

更新日期：2019-08-01 00:00:00

abstract：:Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...

journal_title：Journal of medical economics

authors： Kasahara-Kiritani M,Chaturvedi A,Inagaki A,Wakamatsu A,Jung W

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...

journal_title：Journal of medical economics

authors： McGuire A,Martin M,Lenz C,Sollano JA

更新日期：2015-01-01 00:00:00

abstract：PURPOSE:The purpose of this study was to describe the health-related quality-of-life (QoL) in patients after elective surgery for abdominal aortic aneurysm (AAA) compared to a normal population and to study the association between QoL and number of years since surgery. METHODS:All Danish men who underwent elective sur...

journal_title：Journal of medical economics

authors： Ehlers L,Laursen KB,Jensen MB

更新日期：2011-01-01 00:00:00

abstract：:Aims: Cumulative exogenous factor VIII (FVIII) exposure is an important predictor of developing neutralizing antibodies (inhibitors) to FVIII in patients with persons with hemophilia A (PwHA). The aim of this study was to model the costs of emicizumab versus FVIII prophylaxis and total treatment costs for patients wit...

journal_title：Journal of medical economics

authors： Patel AM,Corman SL,Chaplin S,Raimundo K,Sidonio RF

更新日期：2019-12-01 00:00:00